biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 6.8

an Open Access Journal by MDPI

Small Molecule Drug Discovery with Anti-microbial and Anti-cancer Properties

Guest Editors:

Dr. Vikas Kumar
Basque Center for Materials, Applications, and Nanostructures (BCMaterials), Buil. Martina Casiano, Pl. 3 Parque Científico UPV/EHU Barrio Sarriena, 48940 Leioa, Spain

Dr. Shraddha Parate
Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden

Deadline for manuscript submissions:
closed (31 October 2024)

Message from the Guest Editors

The journey of discovering effective treatments for infectious diseases and cancer has been a challenging and evolving process. Historically, drug discovery often relied on trial and error, resulting in lengthy and resource-intensive endeavors. However, the advent of computational methods has transformed this landscape, ushering in a new era of accelerated and targeted drug development. However, these traditional methods often yielded limited success due to the complex nature of diseases and the immense diversity of potential drug candidates. In the realm of modern drug design, computer-aided molecular modeling and simulation techniques stand as indispensable tools. They empower researchers to identify potential drug candidates with greater efficiency and precision than conventional experimental approaches. Topics of interest for this Special Issue may include, but are not limited to, natural product-derived antimicrobials and anticancer compounds, in silico screening of small molecules, molecular dynamics simulations in rational drug design, machine learning approaches for drug design, network pharmacology for drug discovery, and the structure-based design of PROTACs.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 6.8

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI